Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials - Takeaways - MDSpire

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials

  • By

  • Sujata Purja

  • Yomna Elghanam

  • Eunyoung Kim

  • March 24, 2026

  • 0 min

Share

  • 1

    MRSA is a leading cause of skin and soft tissue infections, significantly impacting healthcare costs and patient outcomes.

  • 2

    Vancomycin has been the standard treatment for MRSA infections, but its limitations raise concerns about its continued efficacy.

  • 3

    Newer anti-MRSA agents offer advantages such as improved pharmacokinetics and safety profiles compared to vancomycin.

  • 4

    This meta-analysis aims to compare the efficacy and safety of vancomycin with alternative treatments for MRSA-confirmed SSTIs.

  • 5

    The study includes rigorous eligibility criteria to ensure comprehensive and reliable data from high-quality randomized controlled trials.

Original Source(s)

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials

  • by Sujata Purja, Yomna Elghanam, Eunyoung Kim

  • March 24, 2026

Related Content

Necrotizing Fasciitis Following Minor Bike Injury

Rapid progression from superficial abrasions to septic shock highlights diagnostic challenges and need for prompt multidisciplinary care.

Dalbavancin Exposure Linked to Higher Success in Bacteremia

Higher day 22 concentrations were associated with improved outcomes, though findings remain exploratory

Analysis of infection characteristics and clinical predictive indicators of different bacterial diabetic foot in Yunnan area